5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule NNMT inhibitor taken orally. NNMT (nicotinamide N-methyltransferase) depletes NAD+ precursors specifically in fat cells, making them metabolically sluggish. 5-Amino-1MQ inhibits NNMT, restoring NAD+ precursor availability in adipocytes and reactivating fat cell metabolism via SIRT1 activation. It is not a peptide — it is a small molecule with oral bioavailability.

Does 5-Amino-1MQ have human clinical trial data?

No published human clinical trials exist as of mid-2026. The evidence base is preclinical: diet-induced obese mice showed ~7% fat mass reduction without food intake reduction (Hong et al., Journal of Medicinal Chemistry, 2015). The mechanism is established in human cell culture. Community use is expanding ahead of the human evidence. This is the central limitation of this compound.

Can 5-Amino-1MQ be stacked with NMN?

The 5-Amino-1MQ + NMN stack is mechanistically coherent. 5-Amino-1MQ inhibits NNMT to prevent NAD+ precursor depletion in fat cells. NMN provides additional NAD+ precursor substrate systemically. They address the NAD+/fat cell metabolism question from two complementary angles. This is one of the better-supported biohacker stacks from a mechanistic standpoint, though both lack robust human clinical trial data for the fat-loss application.

COMPOUND LIBRARY·5-AMINO-1MQ

COMPOUND PROFILE · PEPPERLEDGER

5-Amino-1MQ

Type

Oral small molecule — not a peptide. 5-amino-1-methylquinolinium

Class

NNMT (nicotinamide N-methyltransferase) inhibitor — increases NAD+ precursor availability in fat cells and activates fat cell metabolism

Administration

Oral capsule — primary practical advantage over injectable fat-loss compounds

Half-life

Not well-characterized in humans

Most studied use

Fat loss · Metabolic syndrome · NAD+ metabolism optimization in adipose tissue

Regulatory status

Not FDA-approved · Not WADA-banned · Research chemical · Oral availability makes it distinct from most compounds in this space

Human evidence

Very limited — no published human clinical trials as of mid-2026; mechanism established in human cell culture; preclinical animal data strong

Preclinical evidence

Strong — multiple rodent studies showing fat loss and metabolic improvement without caloric restriction

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is 5-Amino-1MQ?

5-Amino-1MQ is a small molecule NNMT inhibitor — and NNMT (nicotinamide N-methyltransferase) is an enzyme that most people in the biohacker space have never heard of, despite it being one of the most metabolically significant enzymes in fat tissue. NNMT methylates and thereby deactivates nicotinamide — a NAD+ precursor — specifically in fat cells. High NNMT activity in adipose tissue is directly associated with obesity: it depletes the NAD+ precursor pool in fat cells, reducing fat cell metabolism and making them more resistant to lipolysis. 5-Amino-1MQ inhibits NNMT, restoring NAD+ precursor availability in fat cells and reactivating their metabolic machinery.

The appeal is straightforward: a targeted, oral compound that specifically improves fat cell metabolism without requiring caloric restriction or exercise. In diet-induced obese mice, 5-Amino-1MQ reduced fat mass by approximately 7% over several weeks without reducing food intake. Fat cells from treated mice had smaller lipid droplets, higher NAD+ levels, and increased metabolic activity.

The honest picture: this is a compound with strong preclinical evidence and zero published human clinical trial data as of mid-2026. The mechanism is real and novel. The animal data is compelling. But there are no RCTs, no Phase I safety trials, and no published human PK/PD studies. Community use is expanding rapidly ahead of the human evidence — which is the pattern with many emerging compounds, but worth stating clearly.

How it works

NNMT Inhibition — Restoring Fat Cell NAD+ Metabolism

NNMT methylates nicotinamide, converting it to 1-methylnicotinamide and removing it from the NAD+ biosynthesis pathway. In fat cells (adipocytes), high NNMT activity creates a NAD+ precursor deficit — fat cells become metabolically sluggish, resistant to lipolysis, and prone to storing rather than burning fat. 5-Amino-1MQ competitively inhibits NNMT, preserving nicotinamide for conversion to NMN and then NAD+.

SIRT1 and Fat Cell Metabolism

With restored NAD+ from NNMT inhibition, SIRT1 activity in fat cells increases. SIRT1 in adipose tissue promotes lipolysis, reduced lipid droplet size, increased mitochondrial biogenesis, and shifts toward fat oxidation rather than fat storage. This downstream mechanism produces the fat-loss effects seen in animal models — not appetite suppression, but genuine metabolic reactivation of fat tissue.

Adipogenesis Inhibition

Preclinical data suggests 5-Amino-1MQ also inhibits adipogenesis — the differentiation of precursor cells into new fat cells. This may reduce the capacity of fat tissue to expand, not just accelerate fat burning in existing cells. The combination of increased lipolysis and reduced adipogenesis would be mechanistically additive for fat loss.

What the research shows

NO PUBLISHED HUMAN CLINICAL TRIALS

As of mid-2026, there are no published randomized controlled trials in humans for 5-Amino-1MQ. All clinical evidence below is preclinical (rodent models) or mechanistic (human cell culture). This is the central limitation of this compound.

PRECLINICAL EVIDENCE

STUDYBiochemical Pharmacology · 2018

Selective, membrane-permeable NNMT inhibitors (incl. 5-amino-1MQ) reverse high-fat-diet obesity in mice

Neelakantan H et al.

Foundational 5-Amino-1MQ study. The compound showed high cell permeability and NNMT selectivity; in diet-induced obese mice, systemic 5-Amino-1MQ (20 mg/kg three times daily) drove progressive body-weight loss, and in adipocytes 30–60 µM cut lipogenesis by 50–70%. First in-vivo proof that a small-molecule NNMT inhibitor reverses obesity.

View on PubMed →

STUDYNature · 2014

NNMT inhibition prevents diet-induced obesity and metabolic syndrome in mice

Kraus D, Yang Q, Kong D et al.

Earlier study establishing NNMT's role in obesity. High NNMT activity promotes fat cell expansion; NNMT inhibition prevents obesity in mice. Establishes the mechanism 5-Amino-1MQ exploits.

View on PubMed →

STUDYDiabetologia · 2015

NNMT mRNA in human adipose tissue and plasma 1-methylnicotinamide track insulin resistance

Kannt A et al.

Human adipose tissue. NNMT expression and plasma 1-methylnicotinamide (its product) correlate with insulin resistance; type-2-diabetes patients carry ~2× higher NNMT in omental and subcutaneous fat, and insulin-sensitizing interventions (exercise, bariatric surgery) lower it. Human evidence tying the NNMT pathway 5-Amino-1MQ targets to metabolic disease.

View on PubMed →

WHAT THE RESEARCH SHOWS

✓KNOWN

✓NNMT inhibition → NAD+ restoration in fat cells — well-characterized mechanism
✓~7% fat mass reduction without food restriction in obese mice (Hong et al. 2015)
✓High NNMT activity correlates with human obesity and metabolic dysfunction
✓SIRT1 activation in fat cells via restored NAD+ pool
✓Oral bioavailability — practical advantage over injectable fat-loss compounds

?UNCERTAIN

?Human safety and tolerability — no published trials
?Effective human dose and bioavailability
?Whether mouse results translate to meaningful human fat loss
?Long-term safety profile
?Interaction with NAD+ precursor supplementation (NMN, NR)

What the community reports

5-Amino-1MQ has a small but growing community — primarily biohackers specifically interested in its novel NNMT mechanism and oral dosing convenience. Because there's no human trial data, community reports are the primary source of practical information, and they should be understood as early signals rather than established evidence.

—Gradual fat loss over weeks — particularly visceral and stubborn fat; described as subtle but consistent with consistent use

—No appetite suppression — distinct from GLP-1 class compounds; users who don't want hunger changes value this specifically

—Possible energy improvement — consistent with the NAD+ restoration mechanism in fat cells

—No significant side effects reported — the clean preclinical profile appears to translate to minimal adverse effects in early community use

—Often stacked with NMN or NR — NNMT inhibition → NAD+ restoration makes this combination mechanistically coherent

—Highly variable individual response — some users report notable effects, others minimal; consistent with early-stage community data for a compound without established human dosing

Common misconceptions

"5-Amino-1MQ is a proven fat loss compound."

REALITY

Proven in mice, at the preclinical stage in humans. No published human clinical trials. The mechanism is well-characterized and the animal data is strong, but human clinical validation is absent. Community reports are early signals, not clinical evidence.

"It works like GLP-1 drugs for fat loss."

REALITY

Completely different mechanism. GLP-1 agonists suppress appetite centrally — fat loss is primarily via reduced food intake. 5-Amino-1MQ works by restoring fat cell metabolism via NNMT inhibition and NAD+ restoration. No appetite suppression. The fat loss mechanism is metabolic, not dietary.

"5-Amino-1MQ is the same as NMN or NAD+."

REALITY

Different mechanism, complementary effects. NMN provides NAD+ precursors systemically. 5-Amino-1MQ inhibits NNMT specifically in fat cells, preventing the depletion of NAD+ precursors in adipose tissue. They're additive, not redundant.

COMPARE

NAD+ (NMN/NR) — systemic NAD+ precursor supplementation; complementary mechanism. AOD-9604 — injectable GH fragment for targeted fat loss; different mechanism, same general goal. Semaglutide — GLP-1 agonist with the strongest human fat-loss evidence (15% mean weight loss).

AI RESEARCHER PREVIEW

I'm adding 5-Amino-1MQ to my NMN stack. Is there a synergy and what dose should I start with?

The 5-Amino-1MQ + NMN stack is mechanistically coherent — this is one of the better-reasoned biohacker combinations even without clinical trial backing. Here's why the synergy makes sense and what to expect. The mechanism: NNMT in fat cells methylates and deactivates nicotinamide — a NAD+ precursor — preventing it from entering the NAD+ biosynthesis pathway. 5-Amino-1MQ inhibits NNMT, preserving that nicotinamide for conversion to NMN and then NAD+. NMN provides additional NAD+ precursor substrate from the outside. You're addressing the fat cell NAD+ deficit from two directions simultaneously: removing the drain (NNMT inhibition) and adding the supply (NMN). That's additive, not redundant. Dose: 50 mg oral 5-Amino-1MQ once daily is the community starting point. Not 100 mg — start at 50 mg and run 4 weeks before deciding whether to increase. Human dose-response is completely unknown (no published human trials), so the 50–100 mg range that the community uses is an empirical extrapolation from mouse studies, not clinical data. Timing: morning, with or without food. No strong argument for specific meal timing based on available data. Your NMN protocol: continue as established — nothing about adding 5-Amino-1MQ changes NMN dosing or timing. They work on the same pathway through different entry points. What to track: waist circumference is the most sensitive measure for visceral fat changes — measure bi-weekly, same conditions. Body weight weekly. Energy levels as a secondary signal for whether the NAD+ restoration mechanism is producing systemic effects. 4–6 week assessment period before drawing conclusions — fat cell metabolic changes are slow. The honest baseline expectation: this may produce gradual, subtle visceral fat reduction over 8–12 weeks. Not the 7% fat mass in mice — that was in a heavily obese, diet-controlled model. Human translation is unknown.

CONTINUE IN THE APP

Open PepperLedger to track your 5-Amino-1MQ protocol →

Free to join. No credit card. Ask the Researcher about your 5-Amino-1MQ protocol once you're in.

Free to join · No credit card · 23-day Pro trial included